Home/Pipeline/PF-06939926

PF-06939926

Duchenne Muscular Dystrophy

Phase 3Active

Key Facts

Indication

Duchenne Muscular Dystrophy

Phase

Phase 3

Status

Active

Company

Pfizer

About Pfizer

Pfizer's mission is to deliver 'Breakthroughs that change patients' lives' through scientific innovation across a diversified portfolio of therapeutics and vaccines. Its strategic achievements include the rapid development and global commercialization of the COVID-19 vaccine Comirnaty, establishing a leading mRNA platform, and a disciplined pipeline expansion into high-growth areas like obesity and oncology. The company's strategy focuses on sharpening its R&D focus on transformative science, optimizing its cost structure, and deploying capital for strategic business development to drive long-term growth post-pandemic.

View full company profile

Therapeutic Areas

Internal Medicine Oncology Vaccines Inflammation & Immunology Rare Disease

Other Duchenne Muscular Dystrophy Drugs

Drug	Company	Phase	Status
MyoPAXon	Myogenica	Phase 1	Active
DMD Gene Therapy	Kinea Bio	Pre-clinical	Active
NS-051/NCNP-04	NS Pharma	Phase 1/2	Active
UCT-MSC + Biomaterials	Vitti Labs	Phase 2	Active
Myosana Platform for DMD	Myosana Therapeutics	Pre-clinical	Active